Experimental drug aims to tame overactive platelet production

NCT ID NCT06552429

Recruiting now Disease control Sponsor: Xiamen Amoytop Biotech Co., Ltd. Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This phase 2 trial tests two doses of peginterferon alfa-2b in 27 adults with essential thrombocythemia, a blood disorder causing too many platelets, who did not respond to or could not tolerate standard therapy. Participants receive weekly injections for up to 96 weeks. The study measures how the drug moves through the body, its safety, and whether it helps control platelet counts and reduce disease complications.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Peginterferon alfa-2b injection
What this could lead to: If successful, this could offer a new treatment option for people with essential thrombocythemia who cannot take or do not respond to standard therapy.
What could go wrong: This is a small early-phase trial with only 27 participants, so results may not apply broadly. The drug may cause side effects like flu-like symptoms or fatigue, and it is not yet proven to work better than existing treatments.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ESSENTIAL THROMBOCYTHEMIA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

essential thrombocythemia

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ESSENTIAL THROMBOCYTHEMIA

Contacts and locations

Locations

Harbin First Hospital
RECRUITING

Harbin, China
Henan Cancer Hospital
RECRUITING

Henan, China
Nanfang Hospital, Southern Medical University
RECRUITING

Guangzhou, China
Peking Union Hospital, Chinese Academy of Medical Sciences
RECRUITING

Beijing, China
Peking University People's Hospital
RECRUITING

Beijing, China
Ruijin Hospital, Shanghai Jiao Tong University School of Medicine
RECRUITING

Shanghai, China
The First Affiliated Hospital of Zhejiang University School of Medicine
RECRUITING

Zhejiang, China
Union Hospital affiliated to Fujian Medical University
RECRUITING

Fujian, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.